MedImmune
MedImmune signs Incyte oncology deal
May 15, 2014Research and Development, Sales and Marketing AstraZeneca, Cancer, Incyte, MedImmune, oncology
MedImmune, the global biologics R&D arm of AstraZeneca, is to put one of its oncology immunotherapies into development in combination …
AstraZeneca strikes cancer vaccine pact
January 8, 2014Research and Development, Sales and Marketing AstraZeneca, Cancer, MedImmune, oncology
AstraZeneca’s biologics arm MedImmune has struck an oncology research deal with UK biotech company Immunocore. The deal, which could be …
AstraZeneca pays $460m for cancer specialists
October 15, 2013Research and Development, Sales and Marketing ADC, AstraZeneca, Cancer, MedImmune, spirogen
AstraZeneca’s biologics arm MedImmune has bought cancer biotech firm Spirogen and set up a licensing deal with ADC Therapeutics for …
AstraZeneca chooses Cambridge for global HQ
June 19, 2013Research and Development, Sales and Marketing AstraZeneca, Cambridge, MedImmune
AstraZeneca has chosen the Cambridge Biomedical Campus on the outskirts of the city as a new research and corporate hub. …
MedImmune signs diabetes deal
June 18, 2013Research and Development, Sales and Marketing AstraZeneca, MedImmune, diabetes
AstraZeneca R&D subsidiary MedImmune has signed a deal with privately-owned San Francisco-based NGM Biopharmaceuticals to discover novel therapeutics to treat …
MedImmune buys AlphaCore
April 9, 2013Research and Development AlphaCore, AstraZeneca, MedImmune
AstraZeneca’s biologics R&D arm MedImmune has bought private US biotech firm AlphaCore Pharma for an undisclosed sum.The acquisition is part …
Facility of the year: 2013 winners announced
February 4, 2013Manufacturing and Production Biogen, MedImmune, Merck, Novartis, Roche
Three US and three European manufacturing plants have been selected as category winners for the annual Facility of the Year …
MedImmune signs China deal
September 11, 2012Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, China, MedImmune, WuXi, emerging markets, rheumatoid arthritis
MedImmune has sealed a joint venture with Shanghai-based WuXi AppTec to develop a novel biologic for autoimmune and inflammatory diseases …
AstraZeneca’s Fluenz chosen for wider flu immunisation
July 26, 2012Sales and Marketing AZ, AstraZeneca, Cervarix, Gardasil, Lansley, MedImmune
The UK has chosen AstraZeneca’s Fluenz to extend the country’s flu vaccination programme. The health secretary Andrew Lansley said that …
AstraZeneca signs respiratory pact with Amgen
April 5, 2012Research and Development Amgen, AstraZeneca, MedImmune, respiratory
AstraZeneca has bought its way into Amgen’s inflammation portfolio with a $50 million upfront payment to co-develop and commercialise five …
‘Military-inspired’ project wins 2011 Facility of the Year Award
November 9, 2011Manufacturing and Production MedImmune, manufacturing and production
MedImmune’s US manufacturing plant in Frederick, Maryland, has won the 2011 Facility of the Year Award, beating out rival category …
Retaining pharma top talent
February 25, 2011Business Services MedImmune, careers, recruitment, talent retention
Strategies to co-ordinate talent retention differ between companies, and they may not always be as forward-focused as they could – …
AZ accepts $92.5m to settle respiratory dispute
February 18, 2011Sales and Marketing AZ, AstraZeneca, MedImmune, PDL BioPharma, Synagis, patent dispute, respiratory
AstraZeneca’s MedImmune subsidiary is to receive $92.5 million as part of a legal settlement involving its respiratory drug Synagis. PDL …
Bio and clinical plants feature in 2011 FOYA honours
January 25, 2011Manufacturing and Production MedImmune, Merck & Co, Novartis, Pfizer, Roche, Shire HGT, pharma manufacturing
Three US and three European manufacturing plants have been shortlisted for the annual Facility of the Year awards, with the …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
